Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables (2016 - 2025)

China Pharma Holdings' Payables history spans 16 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Payables rose 20.14% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 20.14%, while the annual FY2025 figure was $4.0 million, 20.14% up from the prior year.
  • Payables reached $4.0 million in Q4 2025 per CPHI's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.4 million in Q3 2022 to a low of $349805.0 in Q2 2022.
  • Average Payables over 5 years is $2.7 million, with a median of $2.6 million recorded in 2023.
  • The largest YoY upside for Payables was 970.19% in 2022 against a maximum downside of 66.63% in 2022.
  • A 5-year view of Payables shows it stood at $1.5 million in 2021, then surged by 196.57% to $4.5 million in 2022, then plummeted by 52.98% to $2.1 million in 2023, then skyrocketed by 58.46% to $3.3 million in 2024, then rose by 20.14% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Payables are $4.0 million (Q4 2025), $2.0 million (Q3 2025), and $3.8 million (Q2 2025).